Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer - Abstract

Purpose/Objectives: To examine the trajectory of changes in body composition and metabolic profile in men who receive androgen-deprivation therapy (ADT) for prostate cancer.

Design: Prospective longitudinal design with repeated measures.

Setting: Urban medical center in the southwestern United States.

Sample: 55 men starting radiation therapy for prostate cancer.

Methods: Changes in the parameters of metabolic syndrome were estimated with ADT (n = 31) and non-ADT (n = 24) groups by repeated-measures analysis of variance implemented by general linear mixed-effects models. Models included interactions between groups and follow-up time to test differences between the groups.

Main Research Variables: Body composition and metabolic variables.

Findings: The ADT group demonstrated a transient increase in waist circumference at the nine-month time point and significant changes in measures of insulin resistance were noted at the three month point. Values for diastolic and systolic blood pressure, plasma glucose, high-density lipoprotein, and triglycerides were not altered for either group. Differences in metabolic variables or measures of body composition did not differ significantly between the groups.

Conclusions: The findings demonstrate the development of insulin resistance in men receiving ADT as early as three months after starting ADT.

Implications for Nursing: Addressing survivorship concerns can lead to the development of nursing interventions designed to reduce adverse effects associated with ADT.

Written by:
Harrington JM1, Schwenke DC2, Epstein DR3, Bailey DE4   Are you the author?
1Division of Hematology-Oncology, Health Care System in Arizona. 2Phoenix Veterans Affairs, Health Care System in Arizona. 3College of Nursing and Health Innovation, Arizona State University. 4School of Nursing, Duke University, Durham, NC.

Reference: Oncol Nurs Forum. 2014 Jan 1;41(1):21-9
doi: 10.1188/14.ONF.21-29


PubMed Abstract
PMID: 24368236

UroToday.com Prostate Cancer Section